English
Aims and scope Subscription Info for authors Editorial Board Contacts
International journal of Immunopathology, allergology, infectology.

Immugenin clinical and immunological effects in patients with chronic obstructive lung disease

Yanchanka U.V., Aliakhnovich N.S., Smirnova A.U., Velichinskaya O.G., Novicau D.K.

Vitebsk State Medical University, Vitebsk, Belarus

Randomized single-blind placebo-controlled prospective study of immugenin (L-lysyl-L-glutamic acid) clinical and immunological effects in parallel groups of patients treated with standard protocols of chronic obstructive pulmonary disease (COPD) was performed. Immugenin reduced the number of exacerbations and the number of acute respiratory infections in patients with COPD. Immugenin administration was safe, led to increased serum levels of immunoglobulin A during treatment and normalized initially elevated levels of immunoglobulin G after the treatment completion. Introduction immugenin led to serum TNF-a increasing, and IL-10 decreasing, in contrast to introducing a placebo.

Keywords

Immunomodulator Immugenin, chronic obstructive lung disease, cytokines, ELISA, immunoglobulines

Fulltext in PDF

Open file
Size: 67 KB

Reference

Yanchanka U.V., Aliakhnovich N.S., Smirnova A.U., Velichinskaya O.G., Novicau D.K. Immunopathology, allergology, infectology 2014; 1:15-20